Ghrelin Receptor Blockade Triggers Severe Seizures in Epilepsy Model
Background
Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures, with status epilepticus (SE) representing a life-threatening condition of prolonged or rapidly successive seizures. The ghrelin receptor type 1a (GHSR1a) is known to influence various brain functions, including appetite and memory, but its precise role in modulating seizure susceptibility in epilepsy has remained largely unexplored. This study specifically investigated whether blocking GHSR1a in the brain affects seizure activity and severity in an established electrical kindling model of epilepsy.
Results
The administration of D-Lys3-GHRP-6 significantly exacerbated seizure activity in a dose-dependent manner. Specifically, the GHSR1a antagonist at doses of 0.5 µg/rat and 1 µg/rat induced status epilepticus (SE), a dangerous state of prolonged or rapidly recurring seizures, in 100% of the kindled animals. > The most critical finding was that blocking the ghrelin receptor type 1a with D-Lys3-GHRP-6 at 0.5 µg/rat and 1 µg/rat resulted in status epilepticus in 100% of the kindled rats, a severe and life-threatening seizure condition, whereas 0% of saline-treated controls experienced SE. The antagonist also significantly reduced the latency to generalized tonic-clonic seizures (the time until full-body convulsions began) and significantly prolonged the duration of afterdischarge (the abnormal electrical activity in the brain immediately following a seizure). Even the lowest dose of 0.1 µg/rat significantly intensified seizure severity, indicating a potent pro-convulsant effect of GHSR1a antagonism.
Why It Matters
This study reveals a critical and previously underappreciated role for the ghrelin receptor type 1a (GHSR1a) in modulating seizure susceptibility and severity within the brain. The finding that GHSR1a antagonism dramatically worsens seizures suggests that activating this receptor might offer a protective effect against epilepsy. Understanding this mechanism could pave the way for developing novel anti-epileptic drugs that target ghrelin signaling, potentially by using GHSR1a agonists (compounds that activate the receptor) to prevent or treat severe seizures like status epilepticus. Future research should focus on exploring the therapeutic potential of GHSR1a agonists in various seizure models and ultimately progress towards human clinical trials for epilepsy treatment.